← All trials
NCT05737303
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2027
- First posted
- Feb 21, 2023
- Last posted
- Feb 21, 2023
- Enrollment
- 538
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- Shandong UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Ningbo No. 1 HospitalCollaborator
- Jiaxing Maternity and Child Health Care HospitalCollaborator
- Ningbo Women & Children's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.